Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference19 articles.
1. Brain metastases;Gallego Perez-Larraya;Handb Clin Neurol,2014
2. Extended Survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis;Johung;J Clin Oncol,2016
3. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009
4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012
5. Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: focus on patients with brain metastases;Stefanou;Oncol Lett,2016
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Reply to Y. Yu et al;Journal of Clinical Oncology;2024-06-10
2. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer;Journal of Clinical Oncology;2023-12-02
3. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome;Lung Cancer;2022-07
4. High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience;JTO Clinical and Research Reports;2022-06
5. The Effect of the Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras) Proto-Oncogene, GTPase Genetic Polymorphism on the Safety and Efficacy of Bevacizumab Combination Treatment Regimens for Patients with Nonsquamous, Non-Small Cell Lung Cancer with Brain Metastases;Genetic Testing and Molecular Biomarkers;2022-05-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3